Mepolizumab in patients with severe asthma & BEC ≥150–<300 cells/µL: Benefits at 2 years
Canonica G, Bagnasco D, Lee J, Chupp G, Schleich F, Oppenheimer J, Zhang L, Alfonso-Cristancho R, Howarth P. Mepolizumab in patients with severe asthma & BEC ≥150–<300 cells/µL: Benefits at 2 years. ERJ Open Research 2025, 01390-2024. DOI: 10.1183/23120541.01390-2024.Peer-Reviewed Original ResearchClinically significant exacerbationsBlood eosinophil countMaintenance oral corticosteroidsSevere asthmaRate of clinically significant exacerbationsMedian average daily doseFEV 1Effect of mepolizumabInitiation of mepolizumabProportion of patientsObservational cohort studyReal-world effectivenessClinical trial evidenceForced expiratory volumePoor disease controlMepolizumab treatmentAverage daily doseOral corticosteroidsSingle-armACQ-5Daily doseSignificant exacerbationsEosinophil countMepolizumabCohort study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply